Yan Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Sun has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
C.-C. Zhou
1 shared publicationChen Yao
Peking University First Hospital Beijing China
1 shared publicationEndostar Phase III NSCLC Study Group
1 shared publicationFeng Zhan Qin
Anhai Provincial Cancer Hospital Hefei China
1 shared publicationG.-L. Jiang
1 shared publicationHou Jie Liang
Xinan Hospital 3rd PLA Medical University Chongqing China
1 shared publication
Latest Publications
- Open Access
- 3 May 2013
- Published by Wiley in Thoracic Cancer
- Vol. 4 (4) , 440-448
Long‐term results of a randomized, double‐blind, and placebo‐controlled phase III trial: Endostar (rh‐endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non‐small cell lung cancer
Background: : Phase II‐III trials in patients with untreated and previously treated locally advanced or non‐small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum‐based chemotherapy (NP regimen) with tolerable adverse effects.Methods: Four hundred and eighty six patients were randomized into two arms: study arm A: NP plus Endostar (n = 322; vinorelbine, cisplatin, Endostar), and study arm B: NP plus placebo (n = 164; vinorelbine, cisplatin, 0.9% sodium chloride). Patients were treated every third week for two to six cycles.Results: : Overall response rates were 35.4% in arm A and 19.5% in arm B (P = 0.0003). The median time to progression was 6.3 months for arm A and 3.6 months for B, respectively (P < 0.001). The clinical benefit rates were 73.3% in arm A and 64.0% in arm B (P = 0.035). Grade 3/4 neutropenia, anemia, and nausea/vomiting were 28.5%, 3.4%, and 8.0%, respectively, in Arm A compared with 28.2%, 3.0%, and 6.6%, respectively, in Arm B (P > 0.05). There were two treatment related deaths in arm A and one in arm B (P > 0.05). The median overall survival was longer in arm A than in arm B (P < 0.0001).Conclusion: : Long‐term follow‐up revealed that the addition of Endostar to an NP regimen can result in a significant clinical and survival benefit in advanced NSCLC patients, compared with NP alone.
- 3 May 2013
- Published by Wiley in Thoracic Cancer
- Vol. 4 (4) , 440-448
Open AccessLong‐term results of a randomized, double‐blind, and placebo‐controlled phase III trial: Endostar (rh‐endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non‐small cell lung cancer
Background: : Phase II‐III trials in patients with untreated and previously treated locally advanced or non‐small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum‐based chemotherapy (NP regimen) with tolerable adverse effects.Methods: Four hundred and eighty six patients were randomized into two arms: study arm A: NP plus Endostar (n = 322; vinorelbine, cisplatin, Endostar), and study arm B: NP plus placebo (n = 164; vinorelbine, cisplatin, 0.9% sodium chloride). Patients were treated every third week for two to six cycles.Results: : Overall response rates were 35.4% in arm A and 19.5% in arm B (P = 0.0003). The median time to progression was 6.3 months for arm A and 3.6 months for B, respectively (P < 0.001). The clinical benefit rates were 73.3% in arm A and 64.0% in arm B (P = 0.035). Grade 3/4 neutropenia, anemia, and nausea/vomiting were 28.5%, 3.4%, and 8.0%, respectively, in Arm A compared with 28.2%, 3.0%, and 6.6%, respectively, in Arm B (P > 0.05). There were two treatment related deaths in arm A and one in arm B (P > 0.05). The median overall survival was longer in arm A than in arm B (P < 0.0001).Conclusion: : Long‐term follow‐up revealed that the addition of Endostar to an NP regimen can result in a significant clinical and survival benefit in advanced NSCLC patients, compared with NP alone.
- 1 February 2013
- Published by Elsevier in Lung Cancer
- Vol. 79 (2) , 143-150
Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study
- 1 February 2013
- Published by Elsevier in Lung Cancer
- Vol. 79 (2) , 143-150
Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study
- 3 August 2011
- Published by Wiley in Thoracic Cancer
- Vol. 2 (3) , 116
Comments on “Prior lung disease and lung cancer risk in an occupational‐based cohort in Yunnan, China”: Occupational lung cancer in Yunnan Province, China
- 3 August 2011
- Published by Wiley in Thoracic Cancer
- Vol. 2 (3) , 116
Comments on “Prior lung disease and lung cancer risk in an occupational‐based cohort in Yunnan, China”: Occupational lung cancer in Yunnan Province, China